Business · 06/11/2003Updated: 10/17/2026 · 1 min read
FDA Clears Hyaluronidase for Injection for Approval of Abbreviated New Drug Applications
Summary
The US Food and Drug Administration (FDA) has made a determination that hyaluronidase for injection, marketed as Wydase, was not withdrawn from sale due to safety or effectiveness concerns, paving the way for the approval of abbreviated new drug applications (ANDAs) for the product.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →